血小板减少对癌症相关内脏静脉血栓成人患者出血和血栓结局的影响
这项单中心回顾性队列研究纳入581例癌症相关内脏静脉血栓成年患者,39.5%存在基线血小板减少(血小板<100×10³/μL),39.2%在诊断2周内接受治疗性抗凝。1年主要出血累积发生率10.7%,血栓进展/复发16.2%。多变量分析显示抗凝与主要出血增加(aRR 1.74)及血栓进展/复发减少(aRR 0.55)相关,基线血小板减少与两者均无独立关联。
要点
- 癌症相关内脏静脉血栓患者1年主要出血累积发生率10.7%,血栓进展/复发16.2%。
- 治疗性抗凝与主要出血增加(aRR 1.74;95%CI 1.08-2.81)和血栓进展/复发减少(aRR 0.55;95%CI 0.35-0.86)相关。
- 基线血小板减少(血小板<100×10³/μL)与主要出血及血栓进展/复发均无独立关联。
核心结论
- 癌症相关内脏静脉血栓患者中出血和血栓进展频繁发生。
- 抗凝与主要出血增加及血栓性进展减少相关;血小板减少未影响这些结局。
研究设计与样本
- 单中心、回顾性队列研究,纳入581例癌症合并内脏静脉血栓的成年患者。
- 旨在明确血小板减少对初始癌症相关内脏静脉血栓诊断后1年内主要出血及血栓进展/复发的影响。
主要发现
- 39.5%的患者存在基线血小板减少(诊断内脏静脉血栓15天内血小板<100×10³/μL)。
- 39.2%的患者在内脏静脉血栓诊断后2周内接受治疗性抗凝。
- 1年主要出血累积发生率为10.7%(95%CI 8.2-13.2),血栓进展/复发为16.2%(95%CI 13.2-19.2)。
- 多变量分析中,治疗性抗凝与主要出血增加相关(aRR 1.74;95%CI 1.08-2.81),与血栓进展/复发减少相关(aRR 0.55;95%CI 0.35-0.86)。
- 基线血小板减少与主要出血(aRR 0.76;95%CI 0.43-1.34)及血栓进展/复发(aRR 1.14;95%CI 0.73-1.78)均无独立关联。
关键数值与推荐
- 基线血小板减少定义为内脏静脉血栓诊断15天内血小板<100×10³/μL。
- 采用倾向评分逆概率治疗加权二次分析,血小板减少患者主要出血风险未增加(aHR 0.81;95%CI 0.48-1.39)。
- 将血小板作为时变协变量的多变量分析亦未显示与主要出血相关(aHR 0.89;95%CI 0.55-1.45)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malignancy is a risk factor for splanchnic vein thrombosis (SpVT). Data on the natural history of cancer-associated SpVT are limited. This was a single-center, retrospective cohort study of 581 adult patients with cancer and SpVT. We aimed to characterize the impact of thrombocytopenia on major bleeding and progression or recurrence of SpVT within 1 year of an initial cancer-associated SpVT diagnosis. Baseline thrombocytopenia (platelet <100 × 103/μL within 15 days of SpVT diagnosis) was present in 39.5% of patients. A total of 39.2% of patients received therapeutic anticoagulation within 2 weeks of an SpVT diagnosis. The cumulative 1-year incidence of major bleeding was 10.7% (95% confidence interval [CI], 8.2-13.2) and 16.2% (95% CI, 13.2-19.2) for SpVT recurrence/progression. In the multivariable regression analysis, therapeutic anticoagulation was associated with increased major bleeding (adjusted risk ratio [aRR], 1.74; 95% CI, 1.08-2.81) and decreased progression/recurrence of SpVT (aRR, 0.55; 95% CI, 0.35-0.86). Baseline thrombocytopenia was not independently associated with either major bleeding (aRR, 0.76; 95% CI, 0.43-1.34) or progression/recurrence of SpVT (aRR, 1.14; 95% CI, 0.73-1.78). A secondary analysis using inverse probability of treatment weighting with propensity scores for baseline thrombocytopenia corroborated that patients with thrombocytopenia did not have an increased bleeding risk (adjusted hazard ratio [aHR], 0.81; 95% CI, 0.48-1.39). The multivariable analysis in which platelets were treated as a time varying covariate also did not reveal an association with major bleeding (aHR, 0.89; 95% CI, 0.55-1.45). Bleeding and thrombosis progression were frequent in patients with cancer-associated SpVT. Anticoagulation was associated with increased major bleeding and decreased thrombotic progression; thrombocytopenia did not impact the outcomes.
引用
- Andersen M, Fernandez Turizo MJ, Dodge LE, et al. Impact of thrombocytopenia on bleeding and thrombotic outcomes in adults with cancer-associated splanchnic vein thrombosis. Blood Adv. 2024. PMID: 39418642. doi:10.1182/bloodadvances.2024014249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。